Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Hybrid stent graft, thoracic aortic lesion treatment

PMA Number: P250055 · 2026-06-26

ApplicantArtivion, Inc.
Decision Date2026-06-26
PMA NumberP250055
Product CodeQSK
Device ClassClass 3
Medical SpecialtyU
Advisory CommitteeCV

Device Summary

Hybrid stent graft, thoracic aortic lesion treatment is the device name listed in this FDA 510(k) record. The listed applicant is Artivion, Inc.. It received FDA 510(k) clearance on 2026-06-26. The device is classified under product code QSK. It was reviewed by the CV advisory panel.

Frequently Asked Questions

What is the Hybrid stent graft, thoracic aortic lesion treatment?

Hybrid stent graft, thoracic aortic lesion treatment is a medical device that received FDA 510(k) clearance on 2026-06-26. The listed applicant is Artivion, Inc..

When did Hybrid stent graft, thoracic aortic lesion treatment receive FDA 510(k) clearance?

The clearance date for Hybrid stent graft, thoracic aortic lesion treatment can be found in the official FDA records.

Who is the listed applicant for Hybrid stent graft, thoracic aortic lesion treatment?

The FDA 510(k) record lists Artivion, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Hybrid stent graft, thoracic aortic lesion treatment?

The FDA product code for Hybrid stent graft, thoracic aortic lesion treatment is QSK.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDEDNCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑